Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsRanbaxylaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to
    • Super Six stocks you can bet on August 26

      Super Six stocks you can bet on August 26

      On CNBC-TV18 in Super Six, market gurus Arunesh Madan, Founder and Director of Augment Investment, Abhijit Paul of Brics Securities and Rajesh Jain, EVP Reatail Research, Religare Sec place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Short Ranbaxy Laboratories: Vishal Kshatriya

      Short Ranbaxy Laboratories: Vishal Kshatriya

      Short Ranbaxy Laboratories, says Vishal Kshatriya, Edelweiss.

    • Bull's Eye: 12 intraday picks for the day

      Bull's Eye: 12 intraday picks for the day

      CNBC-TV18 brings you a brand new week of Bull's Eye. It's the popular game show where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Angel Broking positive on Axis Bank,Yes Bank

      Angel Broking positive on Axis Bank,Yes Bank

      Trading tips by Shardul Kulkarni of Angel Broking.

    • Exit Aurobindo Pharma: Salil Sharma

      Exit Aurobindo Pharma: Salil Sharma

      Salil Sharma of Kapoor Sharma and Company feels that one should exit Aurobindo Pharma.

    • Buy telecom stocks on dip: Salil Sharma

      Buy telecom stocks on dip: Salil Sharma

      Buy telecom stocks on dip, says Salil Sharma, Kapur Sharma & Co.

    • Buy Bata India, ITC, Maruti: Nimbus Wealth

      Buy Bata India, ITC, Maruti: Nimbus Wealth

      Rohit Shinde of Nimbus Wealth Management advised buying Idea Cellular, Bata India, ITC, Maruti and Ranbaxy Labs.

    • Ranbaxy has target of Rs 580: Salil Sharma

      Ranbaxy has target of Rs 580: Salil Sharma

      Ranbaxy Laboratories has target of Rs 580, says Salil Sharma of Kapur Sharma & Co.

    • Buy Rel Infra, IDFC, Rel Cap: Indianivesh Securities

      Buy Rel Infra, IDFC, Rel Cap: Indianivesh Securities

      Dharmesh Kant of Indianivesh Securities advised buying Reliance Infrastructure, IDFC, Reliance Capital and Tata Steel.

    • Dharmesh Kant positive on Ranbaxy, Raymond

      Dharmesh Kant positive on Ranbaxy, Raymond

      Dharmesh Kant of Indianivesh Securities is positive on Ranbaxy and Raymond. However, he is bearish on SAIL and Hindalco.

    • Buy Ranbaxy, says Salil Sharma

      Buy Ranbaxy, says Salil Sharma

      Salil Sharma of Kapoor Sharma and Company is of the view that one should buy Ranbaxy.

    • Ranbaxy Labs a best pick in pharma space: Jain

      Ranbaxy Labs a best pick in pharma space: Jain

      Ranbaxy Labs is a best pick in pharma space, says Rajesh Jain, Independent Market Strategist.

    • Short Ranbaxy Laboratories: Vishal Kshatriya

      Short Ranbaxy Laboratories: Vishal Kshatriya

      Short Ranbaxy Laboratories with a target price of Rs 495, says Vishal Kshatriya, Edelweiss

    • Bull's Eye: Stocks to buy today

      Bull's Eye: Stocks to buy today

      Bull's Eye, the popular game show on CNBC-TV18, offer investors a chance to have a look at the stocks that can be added to their portfolio.

    • Ranbaxy may slip further to Rs 490: Datta

      Ranbaxy may slip further to Rs 490: Datta

      Ranbaxy may slip further to Rs 490, says Devangshu Datta, Consulting Editor, Outlook.

    • Sell Ranbaxy Laboratories: Parag Doctor

      Sell Ranbaxy Laboratories: Parag Doctor

      Sell Ranbaxy Laboratories, says Parag Doctor, Motilal Oswal Securities.

    • Super Six: Top chart picks for Tuesday

      Super Six: Top chart picks for Tuesday

      On CNBC-TV18's new show Super Six, market gurus Parag Doctor of Motilal Oswal Securities, Hemen Kapadia of chartpundit.com and Shrikant Chauhan of Kotak Securities, place their bets on two stocks each.

    • Buy Ranbaxy: Somil Mehta

      Buy Ranbaxy: Somil Mehta

      Buy Ranbaxy, says Somil Mehta of Sharekhan.

    • Sun Pharma can rally upto Rs 512: Sharma

      Sun Pharma can rally upto Rs 512: Sharma

      Sun Pharma can rally upto Rs 512, says Salil Sharma, Kapur Sharma & Co. Salil Sahram Polycom.

    • Sun Pharma has strong resistance around Rs 480-485: Sharma

      Sun Pharma has strong resistance around Rs 480-485: Sharma

      Sun Pharma has strong resistance at Rs 480-485, says Jatinder Sharma, Partner at Equity Strategists.

    • Ranbaxy Labs a good bet: Pradhan

      Ranbaxy Labs a good bet: Pradhan

      Ranbaxy Labs a good bet, says Mithil Pradhan, Technical & Derivatives Analyst.

    • Ranbaxy Laboratories can test Rs 540-550: Bothra

      Ranbaxy Laboratories can test Rs 540-550: Bothra

      Ranbaxy Laboratories can test Rs 540-550, says Kunal Bothra of LKP.

    • Buy ITC on dips: Anil Manghnani

      Buy ITC on dips: Anil Manghnani

      Buy ITC on dips, says Anil Manghnani of Modern Shares & Stock Brokers.

    • Buy Ranbaxy on decline: Jain

      Buy Ranbaxy on decline: Jain

      Buy Ranbaxy on decline, says Rajesh Jain, Independent Market Strategist.

    • Buy Glenmark Pharma above Rs 320: Mohindar

      Buy Glenmark Pharma above Rs 320: Mohindar

      Buy Glenmark Pharma above Rs 320, says Rahul Mohindar of Viratechindia.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347